Home› Situations› DIM.PA — Profile and price weak
Situation · 2026-06-12

DIM.PA — Profile and price weak

Discounted for Declining Quality, Not Missed Potential

Updated 2026-06-05 · Ref: Healthcare
Key metrics — 2026-06-05
Peer score
25
Quality pct
32
Valuation pct
19
52w drawdown
-19.4%
21d vs sector
-10.4%
Peer group
Healthcare
Situation summary

Sartorius Stedim Biotech trades at a discount for declining margins and capital returns. The market sees a quality name that has lost its edge. A 31.2% EBITDA margin and 7.8% ROIC are not enough. No turnaround, no rerating.

Published by AssetNext · 2026-04-24

All companies with this signal today

View full list: Profile and price weak →

Related pages for DIM.PA
Full peer analysis for Sartorius Stedim Biotech S.A. →Similar companies to DIM.PADIM.PA peersAll DIM.PA comparisonsSTOXX 600 context
Signal history — last 30 days
Date Signal Peer score Drawdown 21d vs sector
2026-06-05 Profile and price weak 25 -19.4% -10.4%
2026-05-26 Profile and price weak 23 -22.7% -14.3%
2026-05-19 Profile and price weak 22 -27.3% -17.9%

See DIM.PA's full peer analysis

Break down DIM.PA's structural position across all peer dimensions with the interactive app.

Open DIM.PA in AssetNext →